NO982935L - Hyaluronsyre reseptor bindemiddel og anvendelse derav - Google Patents
Hyaluronsyre reseptor bindemiddel og anvendelse deravInfo
- Publication number
- NO982935L NO982935L NO982935A NO982935A NO982935L NO 982935 L NO982935 L NO 982935L NO 982935 A NO982935 A NO 982935A NO 982935 A NO982935 A NO 982935A NO 982935 L NO982935 L NO 982935L
- Authority
- NO
- Norway
- Prior art keywords
- cac
- arg
- binder
- letter code
- code
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 4
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 title 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 229920002674 hyaluronan Polymers 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 108010028295 histidylhistidine Proteins 0.000 abstract 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 abstract 1
- 229940099552 hyaluronan Drugs 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002166155A CA2166155C (en) | 1995-12-27 | 1995-12-27 | Agents binding to hyaluronic acid binding domains and the use thereof |
| PCT/CA1996/000870 WO1997024111A2 (en) | 1995-12-27 | 1996-12-23 | Novel hyaluronic acid receptors binding agents and the use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO982935D0 NO982935D0 (no) | 1998-06-24 |
| NO982935L true NO982935L (no) | 1998-08-27 |
Family
ID=4157242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO982935A NO982935L (no) | 1995-12-27 | 1998-06-24 | Hyaluronsyre reseptor bindemiddel og anvendelse derav |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0874624B1 (ja) |
| JP (1) | JP4210330B2 (ja) |
| KR (1) | KR100476782B1 (ja) |
| AT (1) | ATE255411T1 (ja) |
| AU (1) | AU725478B2 (ja) |
| BR (1) | BR9612355A (ja) |
| CA (1) | CA2166155C (ja) |
| DE (1) | DE69630974T2 (ja) |
| ES (1) | ES2211996T3 (ja) |
| HU (1) | HU226598B1 (ja) |
| IL (1) | IL124828A0 (ja) |
| NO (1) | NO982935L (ja) |
| PL (1) | PL327542A1 (ja) |
| WO (1) | WO1997024111A2 (ja) |
| ZA (1) | ZA9610840B (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2237051A1 (en) * | 1997-12-19 | 1999-06-19 | Eva A. Turley | Enhanced affinity hyaluronan binding peptides |
| SE0101854L (sv) * | 2001-05-28 | 2002-11-29 | Bioneris Ab | Användning av en förening med en negativt laddad region av grupper för behandling av restenos. |
| WO2004060404A1 (ja) * | 2002-12-27 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | 薬物担体 |
| WO2006130974A1 (en) * | 2005-06-08 | 2006-12-14 | Cangene Corporation | Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
| EP3168226A3 (en) | 2010-05-31 | 2017-07-26 | London Health Sciences Centre Research Inc. | Rhamm binding peptides |
| KR101383941B1 (ko) | 2012-03-09 | 2014-04-10 | 동아에스티 주식회사 | 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법 |
| US10766927B2 (en) | 2012-11-25 | 2020-09-08 | The Regents Of The University Of California | Peptides that stimulate subcutaneous adipogenesis |
| US10844102B2 (en) | 2014-05-28 | 2020-11-24 | The Regents Of The University Of California | Peptides, compositions, and methods for stimulating subcutaneous adipogenesis |
| WO2016151478A1 (en) | 2015-03-20 | 2016-09-29 | London Health Sciences Centre Research Inc. | Stapled peptides and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
| CA2122551A1 (en) * | 1994-04-29 | 1995-10-30 | Rudolf Edgar Falk | Clearing of atherosclerosis |
| GB9207949D0 (en) * | 1992-04-09 | 1992-05-27 | Univ Manitoba | Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility |
| EP0778776A1 (en) * | 1994-08-30 | 1997-06-18 | Hyal Pharmaceutical Corporation | Hyaluronic acid and derivatives for modulation of cellular activity |
-
1995
- 1995-12-27 CA CA002166155A patent/CA2166155C/en not_active Expired - Lifetime
-
1996
- 1996-12-23 ZA ZA9610840A patent/ZA9610840B/xx unknown
- 1996-12-23 WO PCT/CA1996/000870 patent/WO1997024111A2/en not_active Application Discontinuation
- 1996-12-23 BR BR9612355-9A patent/BR9612355A/pt not_active Application Discontinuation
- 1996-12-23 AT AT96941564T patent/ATE255411T1/de not_active IP Right Cessation
- 1996-12-23 PL PL96327542A patent/PL327542A1/xx unknown
- 1996-12-23 IL IL12482896A patent/IL124828A0/xx not_active IP Right Cessation
- 1996-12-23 AU AU10912/97A patent/AU725478B2/en not_active Ceased
- 1996-12-23 HU HU9902059A patent/HU226598B1/hu not_active IP Right Cessation
- 1996-12-23 JP JP52393097A patent/JP4210330B2/ja not_active Expired - Fee Related
- 1996-12-23 DE DE69630974T patent/DE69630974T2/de not_active Expired - Lifetime
- 1996-12-23 KR KR10-1998-0704359A patent/KR100476782B1/ko not_active IP Right Cessation
- 1996-12-23 ES ES96941564T patent/ES2211996T3/es not_active Expired - Lifetime
- 1996-12-23 EP EP96941564A patent/EP0874624B1/en not_active Expired - Lifetime
-
1998
- 1998-06-24 NO NO982935A patent/NO982935L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69630974T2 (de) | 2004-10-28 |
| HUP9902059A3 (en) | 2000-07-28 |
| WO1997024111A2 (en) | 1997-07-10 |
| HU226598B1 (hu) | 2009-04-28 |
| HUP9902059A2 (hu) | 2000-04-28 |
| DE69630974D1 (de) | 2004-01-15 |
| KR100476782B1 (ko) | 2005-07-18 |
| CA2166155A1 (en) | 1997-06-28 |
| ES2211996T3 (es) | 2004-07-16 |
| BR9612355A (pt) | 1999-12-28 |
| KR19990072058A (ko) | 1999-09-27 |
| EP0874624A2 (en) | 1998-11-04 |
| AU725478B2 (en) | 2000-10-12 |
| NO982935D0 (no) | 1998-06-24 |
| JP4210330B2 (ja) | 2009-01-14 |
| JP2000506502A (ja) | 2000-05-30 |
| IL124828A0 (en) | 1999-01-26 |
| AU1091297A (en) | 1997-07-28 |
| PL327542A1 (en) | 1998-12-21 |
| WO1997024111A3 (en) | 1997-10-02 |
| CA2166155C (en) | 2008-02-05 |
| ATE255411T1 (de) | 2003-12-15 |
| ZA9610840B (en) | 1997-06-27 |
| EP0874624B1 (en) | 2003-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| BR0011000A (pt) | Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico | |
| BR9710689A (pt) | Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia | |
| RU94027680A (ru) | Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы | |
| BR0309890A (pt) | Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação | |
| NO994275L (no) | Nikotinsyrepreparater til behandling av hyperlipidemi og tilknyttede fremgangsmaater | |
| BR0213100A (pt) | Combinações para o tratamento de distúrbios imuniinflamatórios | |
| BR0014166A (pt) | Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual | |
| NO982935L (no) | Hyaluronsyre reseptor bindemiddel og anvendelse derav | |
| BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
| BR9500436A (pt) | Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico | |
| DE60143078D1 (de) | Pax2 zur behandlung von nierenkrankheiten | |
| KR930702995A (ko) | 세포증식 매트릭스 및 그 용도 | |
| DK1237562T3 (da) | Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme | |
| MXPA00010254A (es) | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. | |
| WO1996020950A3 (en) | Compositions and methods for treating rheumatoid arthritis | |
| JP2007500133A5 (ja) | ||
| GB2079151A (en) | Medication for relief of intra-articular and intra-muscular discomfort | |
| ATE185815T1 (de) | Verwendung einer therapeutischen zusammensetzungen zur behandlung von verbrennungen | |
| RU2268052C2 (ru) | Средство для лечения воспалительных и дегенеративных заболеваний суставов (варианты), способ лечения воспалительных и дегенеративных заболеваний суставов (варианты) и устройство для доставки лекарственного средства к пораженному участку | |
| HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
| BR0111900A (pt) | Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca | |
| ATE260108T1 (de) | Verwendung von citicoline zur behandlung von multipler sklerose | |
| ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| Ochsner et al. | Roentgen therapy for painful conditions of the bones and joints |